Aurobindo Arm Gets Cdsco Sec Recommendation For Biosimilar, ET HealthWorld

[ad_1]

Hyderabad: Aurobindo Pharma Ltd said its wholly owned subsidiary CuraTeQ Biologics Pvt has received a recommendation from the subject experts committee (SEC), which operates under the aegis of CDSCO (Central Drugs Standard Control Organization), for grant of marketing authorisation of biosimilar trastuzumab. The Trastuzumab biosimilar, which is supplied in single dose glass vials containing 150 mg and 420 mg lyophilized powder concentrate for solution for infusion, is a humanised monoclonal antibody for treating metastatic breast cancer and early breast cancer that is human epidermal growth factor receptor 2 positive.

  • Published On Jan 19, 2024 at 03:42 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles


Scan to download App


[ad_2]

Leave a Reply

Your email address will not be published. Required fields are marked *